Teropavimab
- Generic Name
- Teropavimab
Antiretrovirals Combined With Antibodies for HIV-1 Cure In Africa
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 135
- Registration Number
- NCT06205602
- Locations
- 🇧🇼
Gaborone CRS (12701), Gaborone, Botswana
🇿🇦University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101), Johannesburg, Gauteng, South Africa
🇿🇦CAPRISA eThekwini CRS (31422), Durban, KwaZulu-Natal, South Africa
Pausing Antiretroviral Treatment Under Structured Evaluation
- Conditions
- HIV-1-infection
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 48
- Registration Number
- NCT06031272
- Locations
- 🇧🇼
Gaborone CRS (12701), Molepolole, Botswana
🇲🇼Blantyre CRS (30301), Blantyre, Malawi
🇲🇼Lilongwe Malawi CRS (12001), Lilongwe, Malawi
A Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV Infections
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 83
- Registration Number
- NCT05729568
- Locations
- 🇺🇸
Ruane Clinical Research Group, Inc., Los Angeles, California, United States
🇺🇸Can Community Health Care, Fort Lauderdale, Florida, United States
🇺🇸Emory University Hospital Midtown Infectious Disease Clinic, Atlanta, Georgia, United States
A Study to Evaluate the Safety and Effects of Repeated Doses of 3BNC117-LS and 10-1074-LS on Persistent Viral Reservoirs in People Living With HIV and on Suppressive Antiretroviral Therapy
- Conditions
- HIV-1
- Interventions
- First Posted Date
- 2022-11-10
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 200
- Registration Number
- NCT05612178
- Locations
- 🇺🇸
The Rockefeller University, New York, New York, United States
🇺🇸National Institutes of Health Clinical Center, Bethesda, Maryland, United States
3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)
- Conditions
- Human Immunodeficiency Virus
- Interventions
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 28
- Registration Number
- NCT05245292
- Locations
- 🇺🇸
Weill Cornell Medicine, Cornell Clinical Trials Unit, New York, New York, United States
🇺🇸The Rockefeller University, New York, New York, United States
🇺🇸Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, United States
Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI
- Locations
- 🇺🇸
Alabama CRS, Birmingham, Alabama, United States
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
- First Posted Date
- 2021-03-26
- Last Posted Date
- 2021-03-26
- Lead Sponsor
- Frontier Biotechnologies Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT04819347
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
Study to Evaluate the Safety and Efficacy of Teropavimab and Zinlirvimab in Combination With Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
- Conditions
- HIV-1 Infection
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 32
- Registration Number
- NCT04811040
- Locations
- 🇺🇸
Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The Brody School of Medicine at East Carolina University, ECU Adult Specialty Care, Greenville, North Carolina, United States
🇺🇸Be Well Medical Center, Berkley, Michigan, United States
3BNC117-LS and 10-1074-LS in Viremic HIV-infected Individuals
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Rockefeller University
- Target Recruit Count
- 6
- Registration Number
- NCT04250636
- Locations
- 🇺🇸
Weill Cornell Medical Center Clinical Trials Unit-CLOSED SITE, New York, New York, United States
🇺🇸Perelman School of Medicine University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸The Rockefeller University, New York, New York, United States
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
- Conditions
- HIV-1-infection
- Interventions
- Biological: 10-1074-LS-JBiological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1Biological: Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 3Biological: Combination 3BNC117-LS-J and 10-1074-LS-JBiological: Placebo
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- International AIDS Vaccine Initiative
- Target Recruit Count
- 225
- Registration Number
- NCT04173819
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇿🇦Wits Reproductive Health and HIV Institute, Johannesburg, South Africa
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.